Department of Dermatology, Saarland University Medical Center, 66421 Homburg, Germany.
Health Management, German University for Prevention and Health Management (DHfPG), 66123 Saarbruecken, Germany.
Nutrients. 2023 Sep 14;15(18):3986. doi: 10.3390/nu15183986.
To obtain reliable data that allow health authorities to re-evaluate recommendations for oral vitamin D uptake, we conducted a meta-analysis to investigate the impact of supplementation on serum 25-hydroxyvitamin D (25(OH)D) levels in healthy adults in Europe. Of the publications identified (n = 4005) in our literature search (PUBMED, through 2 January 2022), 49 primary studies (7320 subjects, 73 study arms) were eligible for inclusion in our meta-analysis. The risk of bias was assessed using the Cochrane RoB tool based on seven categories, according to which each study is rated using three grades, and overall was rated as rather low. The median duration of intervention was 136.78 days (range, 1088 days); the mean weighted baseline 25(OH)D concentration and mean age were 33.01 vs. 33.84 nmol/L and 46.8 vs. 44.8 years in the vitamin D and placebo groups, respectively. Using random-effects models, 25(OH)D levels were increased by 36.28 nmol/L (95% CI 31.97-40.59) in the vitamin D group compared to the placebo, with a relative serum increment of 1.77 nmol/L per 2.5 μg of vitamin D daily. Notably, the relative serum 25(OH)D increment was affected by various factors, including the dosage and baseline serum 25(OH)D concentration, decreasing with increasing vitamin D doses and with increasing baseline serum levels. We estimate that supplementation in all healthy adults in Europe with appr. 25 μg of vitamin D (1000 IU) daily would raise serum 25(OH)D levels in 95% of the population to ≥50 nmol/L. Our work provides health authorities with reliable data that can help to re-evaluate recommendations for oral vitamin D supplementation.
为了获取可靠的数据,以便卫生当局重新评估口服维生素 D 摄入的建议,我们进行了一项荟萃分析,以调查补充剂对欧洲健康成年人血清 25-羟维生素 D(25(OH)D)水平的影响。在我们的文献检索(PUBMED,截至 2022 年 1 月 2 日)中,确定了 4005 篇出版物,其中 49 项主要研究(7320 名受试者,73 个研究组)符合纳入荟萃分析的标准。使用基于七个类别的 Cochrane RoB 工具评估偏倚风险,根据该工具,每项研究均使用三个等级进行评级,总体评级为低风险。干预的中位持续时间为 136.78 天(范围为 1088 天);维生素 D 组和安慰剂组的加权基线 25(OH)D 浓度和平均年龄分别为 33.01 和 33.84 nmol/L,46.8 和 44.8 岁。使用随机效应模型,与安慰剂组相比,维生素 D 组的 25(OH)D 水平增加了 36.28 nmol/L(95%CI 31.97-40.59),血清中 25(OH)D 浓度相对增加了 1.77 nmol/L/每天 2.5 μg 维生素 D。值得注意的是,血清 25(OH)D 相对增加受多种因素影响,包括剂量和基线血清 25(OH)D 浓度,随着维生素 D 剂量的增加和基线血清水平的升高而降低。我们估计,在欧洲所有健康成年人中补充约 25 μg 维生素 D(1000 IU)/天,将使 95%的人群的血清 25(OH)D 水平提高至≥50 nmol/L。我们的工作为卫生当局提供了可靠的数据,有助于重新评估口服维生素 D 补充的建议。